Vishwas Seshadri Buys 10,000 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Vishwas Seshadri bought 10,000 shares of the business’s stock in a transaction on Thursday, April 25th. The shares were acquired at an average price of $3.20 per share, with a total value of $32,000.00. Following the completion of the purchase, the chief executive officer now directly owns 538,260 shares of the company’s stock, valued at $1,722,432. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Abeona Therapeutics Price Performance

Shares of ABEO stock traded up $0.34 on Monday, reaching $3.60. 658,553 shares of the company were exchanged, compared to its average volume of 439,897. The company has a market cap of $98.46 million, a price-to-earnings ratio of -1.38 and a beta of 1.49. The company has a 50-day moving average of $7.23 and a 200-day moving average of $5.62. Abeona Therapeutics Inc has a one year low of $2.83 and a one year high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.13). As a group, sell-side analysts predict that Abeona Therapeutics Inc will post -2.05 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its stake in Abeona Therapeutics by 84.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock worth $13,682,000 after purchasing an additional 1,488,834 shares during the last quarter. AIGH Capital Management LLC lifted its stake in Abeona Therapeutics by 77.7% in the third quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock worth $4,779,000 after purchasing an additional 496,278 shares during the last quarter. Citigroup Inc. increased its position in shares of Abeona Therapeutics by 125.0% in the third quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company’s stock valued at $1,894,000 after acquiring an additional 250,000 shares during the period. Barclays PLC increased its position in shares of Abeona Therapeutics by 100.0% in the third quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after acquiring an additional 185,638 shares during the period. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Abeona Therapeutics in the third quarter valued at about $648,000. 80.56% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ABEO has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $36.00 price target on shares of Abeona Therapeutics in a report on Tuesday, April 23rd. StockNews.com downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.